Physician profile
Jana M Robison
NPI 1467177469
$5,272.29
in general payments reported to CMS, 2019-2025
18 companies · $2,630 in 2025
The $2,630 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $873 · 2024: $1,770 · 2025: $2,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,134 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,133.53 |
| Education | $138.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,222.00 | 2023-2025 | Caplyta |
| Alkermes, INC. | $474.78 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $456.39 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $418.24 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $414.17 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $409.16 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $403.62 | 2023-2025 | Auvelity |
| Lundbeck LLC | $380.80 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $269.51 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $160.14 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $142.44 | 2025 | Qelbree |
| Neurocrine Biosciences, INC. | $138.07 | 2025 | |
| Vanda Pharmaceuticals INC. | $100.85 | 2025 | Fanapt |
| Bausch Health US, LLC | $81.23 | 2023-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $74.52 | 2024-2025 | Dyanavel Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $57.40 | 2023 | Azstarys |
| Janssen Scientific Affairs, LLC | $35.55 | 2025 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $33.42 | 2023-2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jana Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.